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Abstract
A confirmed Ebola haemorrhagic fever (EHF) outbreak in Bundibugyo, Uganda, November 2007–February 2008, was caused
by a putative new species (Bundibugyo ebolavirus). It included 93 putative cases, 56 laboratory-confirmed cases, and 37
deaths (CFR=25%). Study objectives are to describe clinical manifestations and case management for 26 hospitalised
laboratory-confirmed EHF patients. Clinical findings are congruous with previously reported EHF infections. The most
frequently experienced symptoms were non-bloody diarrhoea (81%), severe headache (81%), and asthenia (77%). Seven
patients reported or were observed with haemorrhagic symptoms, six of whom died. Ebola care remains difficult due to the
resource-poor setting of outbreaks and the infection-control procedures required. However, quality data collection is
essential to evaluate case definitions and therapeutic interventions, and needs improvement in future epidemics.
Organizations usually involved in EHF case management have a particular responsibility in this respect.
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Introduction
Filoviridae family members are characterised by filamentous
enveloped particles with a negative-sense single-stranded RNA
genome. They are divided into two genera, Ebolavirus and
Marburgvirus, respectively causing Ebola and Marburg haemor-
rhagic fever (EHF, MHF) in human and non-human primates [1].
Filovirus haemorrhagic fever (FHF) outbreaks are characterised by
secondary transmission and high case fatality [2,3], although
species-specific case fatality ratios (CFR) vary considerably: Zaire
ebolavirus (ZEBOV; 80–90%) [2,4,5], Sudan ebolavirus (SEBOV; 40–
65%) [2], Bundibugyo ebolavirus (BEBOV; 25%) [6–8], Co ˆte d’Ivoire
ebolavirus (CIEBOV; 0%; based on a single patient) [9–11], Reston
ebolavirus (REBOV; 0%; possibly non-pathogenic for humans) [12–
16], and Lake Victoria marburgvirus (MARV; 20–88%) [17–20]. To
date, 35 FHF outbreaks are known to have occurred in humans
(24 EHF and 11 MHF), all in or originating from sub-Saharan
Africa [2,21–27].
Suspect and laboratory-confirmed patient categorisation
In sub-Saharan Africa, when a medical professional suspects a
filovirus infection, the patient’s blood sample is typically sent
abroad to a biosafety level-4 (BSL-4) laboratory for diagnostic
confirmation. If positive, an outbreak is declared and an
international response initiated, consisting of case identification
and contact tracing, with isolation and treatment of suspect and
laboratory-confirmed patients in a filovirus ward [28–33].
Due to delays between outbreak onset, recognition, and
response, some individuals potentially infected with filovirus
convalesce, die and are buried, or are lost to follow-up before
having their blood sampled for disease confirmation. Likewise, if
clinical disease and outcome occur prior to a filovirus ward’s
existence or functionality, not all patients are hospitalised and
treated on a filovirus ward. Outbreaks therefore habitually
conclude with putative, suspected, and laboratory-confirmed
patient categorisations, with only some patients receiving support-
ive treatment on a filovirus ward.
Once case identification and contact tracing activities com-
mence, individuals matching epidemiological and clinical case
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assessment and, when appropriate, categorised as a suspected
FHF patient while a blood sample is drawn and sent for laboratory
confirmation. Diagnostic results are typically available within four
hours from an on-site laboratory, 48 hours from a laboratory
elsewhere in the country, or a week for samples sent abroad
[33,34]. Patients with negative test results are discharged and
assessed for an alternative illness or remain on the ward and are
re-tested if FHF clinical suspicion remains. Laboratory-confirmed
patients remain hospitalised on the filovirus ward until virus
clearance and recovery or death.
Standard case management
In the absence of specific antifiloviral therapy, filovirus ward
clinicians provide suspect and laboratory-confirmed patients with
the supportive care regime administered during the 1995 EHF
outbreak in Kikwit, Democratic Republic of the Congo and
subsequent outbreaks, consisting of oral medication, oral fluid
rehydration, nutritional supplementation, and psychosocial sup-
port [26,29–31]. Oral medication includes those that alleviate
FHF-related symptoms such as nausea and vomiting (e.g.
metoclopramide and promethazine), dyspepsia (e.g. aluminium
hydroxide, cimetidine, ranitidine, and omeprazole), anxiety,
agitation, or confusion (e.g. diazepam, chlorpromazine), and pain
(e.g. paracetamol, tramadol, and morphine), when indicated. In
addition to supportive care, oral artemether/lumefantrine for
uncomplicated malaria and an oral antibiotic (e.g. amoxicillin,
cotrimoxazole, cefixime, or ciprofloxacin) are uniformly adminis-
tered due to the customary absence of an on-site laboratory
capable of safely processing biological samples for alternative
diagnoses. Recently expanded, supportive care may also include
prevention and treatment of dehydration via intravenous (IV)
fluids, nasogastric delivery of nutritional and vitamin supplemen-
tation, and IV administration of medication for optimum drug
delivery when clinically indicated [26,29].
Improving knowledge of human clinical manifestations
and case management
Limited quality FHF clinical data from human outbreaks have
been collected, analysed, and published, partly due to safety
concerns about transferring paper-based clinical records outside
the filovirus ward [26]. Records have been destroyed as potential
fomites, not recorded, or haphazardly logged [26]. As a result,
most detailed descriptions of clinical manifestation have been from
laboratory-based studies of non-human primates [35–39] and a
limited number of human patients (e.g. ZEBOV [28,40–52],
SEBOV [53–56], CIEBOV [9], and MARV [19,33,57–67]).
Substantial uncertainties remain regarding human FHF incu-
bation periods and symptom frequency, onset, and duration.
Retrospectively collected FHF clinical data are of questionable
validity and reliability due to reporting and recall biases
[41,48,49,53,54]. Although some outbreak analyses have yielded
symptom frequency and duration [9,19,40,49,53,55], numerous
others yielded only frequency data [24,28,33,41,45–48,54]. Point
and period prevalence of symptoms (e.g. at admission to the
filovirus ward, during hospital stay) fail to document the clinical
course of disease. Understanding human FHF symptomatology is
crucial for advancing outbreak control measures and administer-
ing supportive treatment based on symptom presentation and
disease severity [33].
Although anecdotal evidence suggests supportive treatment
increases FHF survival, its effectiveness has not been assessed in an
outbreak setting [21,29,46]. More data on human clinical
manifestations and treatment effectiveness are needed to improve
response to these poorly understood diseases.
The 2007–2008 Bundibugyo outbreak
On 29 November 2007, the Uganda Ministry of Health (MoH)
and the World Health Organization (WHO) confirmed an
outbreak of EHF in Bundibugyo District, western Uganda, and
responded in collaboration with Me ´decins Sans Frontie `res (MSF),
the Uganda Virus Research Institute (UVRI), the United States
Centers for Disease Control and Prevention (CDC), and others
[68]. On 20 February 2008, the outbreak concluded with 93
putative and 56 laboratory-confirmed cases (30 of whom were
hospitalised) and 37 deaths, yielding a 25% CFR [69,70]. Most
cases originated from Bundibugyo and Kikyo, towns of approx-
imately 16,000 and 5,700 inhabitants respectively. Bundibugyo is
situated at the base of the Rwenzori Mountains, and Kikyo
25 kilometres within them. An Ebola ward was set up and
maintained at each location throughout the outbreak response
[70]. Genetic sequencing of viral RNA, conducted at CDC
Atlanta, confirmed that the virus causing the Bundibugyo
outbreak differed from any known ebolavirus (EBOV) species
and was, although most closely related to CIEBOV, therefore
proposed as a new EBOV species provisionally named Bundibugyo
ebolavirus (BEBOV) [71].
Study rationale and objectives
This outbreak is the first known observation of human disease
caused by this putatively novel EBOV species. Thus, documenting
clinical manifestations of BEBOV infection furthers knowledge of
human FHF symptomatology, while describing the implemented
FHF case management strategy identifies its merits and short-
comings, a baseline imperative for improving and assessing the
effectiveness of supportive case management. Pending antifiloviral
therapy development, this may be the only way for future patients
to receive better care. The objectives of this secondary analysis of
patient data are to (i) describe patient demographics and contact
histories; (ii) document symptoms from onset to clinical outcome;
(iii) describe case management on the Ebola ward; and (iv)
recommend strategies for improving data collection in future FHF
outbreaks.
Methods
Ethics statement
The Uganda National Health Research Organization and the
Ethics Review Boards of Me ´decins Sans Frontie `res and London
School of Hygiene & Tropical Medicine provided ethics approval
for a posteriori analyses of the outbreak’s anonymous and routinely
collected clinical and epidemiological data. As no additional data
were collected for research purposes and all data were anonymous
before analysis, the ethical review boards waived the need for
patients’ consent.
Study population and data collection
Study subjects were patients hospitalised on Bundibugyo or
Kikyo Ebola wards with subsequent EHF laboratory confirmation.
The case definitions to identify suspected EHF cases in
Bundibugyo District were: (i) an epidemiological link to an
individual potentially infected with EBOV and at least three
general symptoms (i.e. asthenia, anorexia, myalgia/arthralgia,
diarrhoea, abdominal pain, nausea, vomiting, headache, dyspha-
gia, dyspnoea, conjunctivitis, jaundice, hiccups); or (ii) fever plus at
least three of the general symptoms listed above; or (iii) fever plus
unexplained haemorrhage. Individuals fulfilling one or more
Ebola Clinical Manifestations and Case Management
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assessed. Suspected cases further corroborated by clinical assess-
ment had a venipuncture-acquired blood sample drawn and sent
to the UVRI/CDC laboratory in Entebbe, Uganda for biological
confirmation by polymerase chain reaction (PCR), antigen
detection by enzyme-linked immunosorbent assay (ELISA), or
IgM-capture ELISA [69,71]. Laboratory results were available
three to five days after sample extraction.
The makeshift Bundibugyo and Kikyo Ebola wards became
fully functional following implementation of WHO and MSF
infection control and treatment protocols [3,31]. Study subjects
were hospitalised on (i) a makeshift ward for the entirety of their
stay; (ii) a makeshift ward that became fully functional during their
stay; or (iii) a fully functional ward for the entirety of their stay.
Differences between fully functional and makeshift wards were
additional medical supplies, case management as described in the
introduction, and standardised data collection [48]. Data were
recorded by MoH staff on makeshift wards and MoH, WHO, and
MSF staff on fully functional wards (Figure 1).
Study variables and data analysis
Data were collected on patient demographics, contact history,
symptoms (self-reported from disease onset until presentation at
the Ebola ward or observed by healthcare workers from admission
until clinical outcome), treatment, patient monitoring, and clinical
outcome.
Demographic variables were age, gender, residence, occupa-
tion, and Ebola ward. Contact history with an individual
potentially infected with EBOV was categorized as none, indirect
(i.e. via fomite), direct, and direct during funeral practices [33].
Symptoms were categorised as general or haemorrhagic. Sup-
portive treatment was categorised as EHF-related symptom
alleviation, antibiotics, antimalarials, and dehydration manage-
ment. Nutritional and psychosocial support data were not
collected. Patient monitoring data were axillary body temperature
(i.e. fever defined as axillary body temperature $38.0u Celsius),
heart rate (beats per minute), respiratory rate (breaths per minute),
and blood pressure (mmHg). Clinical outcome was defined as
death or survival on discharge from the Ebola ward.
Data were analysed using Microsoft Excel and StataH 11.0
(StataCorp Texas) to describe symptom frequencies, duration, and
pattern and to determine associations between demographics,
symptoms, or treatment and clinical outcome using exact logistic
regression for small samples. Simple binomial logistic regression
was used to determine probability of death by number of
symptoms. Fisher’s exact p-values of ,0.05 were considered
statistically significant.
Results
Our study sample included 26 of the 30 hospitalised laboratory-
confirmed EHF patients. Four patients were excluded for lacking
symptom and/or clinical outcome data. Self-reported symptoms
were recorded for 15 patients, clinically observed symptoms for 21
patients, and treatment details for 19 patients.
Demographics and contact history
Table 1 presents self-reported demographics, days before
seeking treatment at an Ebola ward, and contact histories of the
26 patients, stratified by clinical outcome. Median age was 37
years (range 20–66) and 73% were male. No female patients were
known to be pregnant, though one had miscarried the day prior to
her Ebola ward admission and another was breastfeeding. Most
(73%) were isolated in the Bundibugyo Ebola ward. Half of
patients (6/12; 50%) with occupation recorded were health
workers, and five of these (83%) were male. All 14 patients
(100%) with a recorded contact history reported direct contact
and/or contact during funeral practices, whereas 12 patients
(38%) reported no known contact. Demographic and contact
history variables were not associated with clinical outcome
(Fisher’s exact p-value range: 0.25–0.69).
Course of disease and clinical manifestations
Eleven of the 26 patients died (CFR=42%). The median
duration of disease was 9 days (range 3 to 20) from self-reported
symptom onset to death for 11 patients and 9.9 days (range 2 to
21) from self-reported onset to last recorded symptom prior to
discharge for 15 surviving patients. Patients presented to an Ebola
ward after a mean self-reported delay of 3.5 days (range 0 to 8)
following symptom onset. Available data do not indicate that
delayed hospitalisation increased probability of death (e.g.
differences were not significant for patients who died after being
admitted four to eight days (4/9; 44%) versus zero to three days
(4/13; 31%) after symptoms reportedly commenced [Fisher’s exact
p-value 0.66; Table 1]).
Table 2 presents all recorded patient symptoms. The left side
shows frequency, usual day of onset, and mean duration in days of
self-reported symptoms among 15 patients. The most frequently
reported general symptoms were fever, nausea/vomiting and non-
bloody diarrhoea (11/15; 73% each), abdominal pain (9/15;
60%), and conjunctivitis (5/15; 33%). Each self-reported symptom
was experienced for a median of three to four days prior to
hospitalisation. Although no individual self-reported symptom was
associated with clinical outcome (Fisher’s exact p-value range
0.23–1.00), each additional self-reported symptom significantly
doubled the odds of death (OR 2.14; 95%CI: 1.02–8.18).
The centre of Table 2 presents frequency, pattern (continuous
versus intermittent), and mean duration in days of clinically
observed symptoms among 21 patients, from presentation to the
Ebola ward until clinical outcome. Frequent symptoms included
severe headache (20/21; 95%), asthenia (18/21; 86%), myalgia
(16/21; 76%), dysphagia and appetite loss (15/21; 71% each), and
non-bloody diarrhoea (14/21; 67%). Each symptom lasted a mean
duration of 3.5–8 days (range 1–13). Less frequent clinically
observed general symptoms (conjunctivitis, chest pain, cough, and
right upper-quadrant pain) had relatively protracted duration
Figure 1. Filovirus ward clinicians administering supportive
treatment while concurrently recording clinical data during the
Bundibugyo Uganda 2007–08 Ebola haemorrhagic fever
outbreak. Photo by Claude Mahoudeau.
doi:10.1371/journal.pone.0052986.g001
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recorded at least once while hospitalised, one patient (10%)
developed fever for one day.
The right of Table 2 and Figure 2 present symptom frequency
from self-reported onset to clinical outcome (i.e. self-reported and
clinically observed) for the 26 study-patients. The most frequently
experienced symptoms were non-bloody diarrhoea (81%), severe
headache (81%), and asthenia (77%), while Figure 3 presents their
median duration.
No self-reported or clinically observed symptom or combination
of symptoms, other than any haemorrhage (Fisher’s exact p-value
0.05), was associated with clinical outcome (Fisher’s exact p-value
range: 0.37–1.00). However, similarly to self-reported symptoms,
for each additional clinically observed symptom, the odds of death
increased by approximately 31% (OR 1.31; 95%CI: 1.04–1.82).
Haemorrhagic symptoms
Seven patients experienced self-reported and/or clinically
observed haemorrhagic symptoms, six of whom died (Table 2).
Haemorrhagic patients had twelve times greater odds of dying
than those not experiencing any haemorrhagic symptom (86%
versus 33%; OR 12.0, exact 95%CI: 1.02–590; data not shown).
Three patients self-reported haemorrhagic symptoms prior to
admission while five patients were clinically observed with
haemorrhagic symptoms during hospitalisation. The one surviving
patient self-reported and was clinically observed with epistaxis
(Table 2). Of the two patients who self-reported haemorrhage and
later died, one reported melaena, while the other reported
haematemesis, epistaxis, and postpartum bleeding (Table 2). In
neither patient were haemorrhagic symptoms clinically observed
during hospitalisation. Of the three patients who self-reported a
haemorrhagic symptom, two presented to an Ebola ward within
24 hours of self-reported bleeding onset, while one tolerated
melaena for three days prior to presenting. Each of these three
patients had a self-reported median of one day of fever prior to
Ebola ward presentation.
Clinically observed haemorrhagic symptoms (Table 2; Figure 4)
included melaena and prolonged bleeding at an injection site (2/
21; 10% each), and haematemesis, bleeding gums, haemoptysis,
haematuria, haematoma, and postpartum vaginal bleeding (1/21;
Table 1. Self-reported demographics, days before seeking treatment at an Ebola ward, and contact histories of 26 patients with
laboratory-confirmed Ebola haemorrhagic fever, Bundibugyo District, Uganda (November 2007–February 2008).
Characteristics
Survived
n=15 (row%
1)
Died
n=11 (row%
1)
Total
n=26 (col%
1) Odds ratio (95%CI)
2*
Median age (range) 35 (21–50) 39 (20–66) 37 (20–66) 1.03 (0.96–1.11)
Gender
Female 4 (57) 3 (43) 7 (27) baseline
Male 11 (58) 8 (42) 19 (73) 0.97 (0.12–8.56)
Occupation
Health worker 3 (50) 3 (50) 6 (23) baseline
Farmer 0 (0) 2 (100) 2 (8) 1.68 (0.11-inf)
Other 3 (75) 1 (25) 4 (15) 0.88 (0.51–1.31)
Unknown 9 (64) 5 (36) 14 (54) 0.99 (0.97–1.02)
Days before seeking treatment at Ebola ward
3
0–3 days symptomatic 9 (69) 4 (31) 13 (50) baseline
4–8 days symptomatic 5 (56) 4 (44) 9 (35) 1.75 (0.22–14.6)
Unknown 1 (25) 3 (75) 4 (15) 1.29 (0.86–2.35)
Ebola ward
Bundibugyo ward 11 (58) 8 (42) 19 (73) baseline
Kikyo ward 4 (57) 3 (43) 7 (27) 1.03 (0.12–8.14)
Symptoms data records
Only self-reported 3 (60) 2 (40) 5 (19) baseline
Only clinically-observed 6 (60) 4 (40) 10 (39) 1.0 (0.07–17.3)
Both recorded 6 (55) 5 (45) 11 (42) 1.11 (0.31–4.53)
Contact history
No known contact 7 (58) 5 (42) 12 (46) baseline
Known contact 8 (57) 6 (43) 14 (54) 1.16 (0.18–8.00)
Direct (non-funeral) 6 (55) 5 (45) 11 (79) ..
Direct (funeral practices) 2 (67) 1 (33) 3 (21) ..
NB:
*Results significant at p,0.05.
1Except age, where brackets include the range.
2OR calculates odds ratio for fatal outcome and 95% confidence intervals, comparing exposed to reference (baseline or OR=1) patients, using exact methods and
Fisher’s exact p-values for small sample sizes (confounders have not been adjusted for due to small cell sizes).
3Patient’s villages were all located within a one-hour walk of Bundibugyo or Kikyo towns.
doi:10.1371/journal.pone.0052986.t001
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PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e529865% each). Of the four patients who were only clinically observed
with haemorrhagic symptoms, the first was observed with bleeding
gums; the second with prolonged bleeding from an injection site;
the third with melaena, haematemesis, and prolonged bleeding
from an injection site; and the fourth with melaena, haemoptysis,
haematuria, haematoma, and postpartum bleeding. Petechiae
were not observed.
Figure 2. Frequency of non-haemorrhagic symptoms from self-reported day of symptom onset to clinical outcome, as absolute
numbers and percentages, among symptomatic (9 deceased and 12 surviving) laboratory-confirmed Ebola haemorrhagic fever
patients, Bundibugyo District, Uganda, November 2007–February 2008. Note changes in denominator between self-reported and clinically
observed sections.
doi:10.1371/journal.pone.0052986.g002
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Of the 19 laboratory-confirmed patients with treatment details
recorded, 18 (95%) were administered paracetamol to alleviate
pain and one patient (1%) received cimetidine for dyspepsia
(Table 3). No other medication was administered to alleviate
Ebola-related symptoms. Antibiotics were administered to seven
patients (37%) for potential concomitant infections. Antimalarials
were administered to 11 patients (58%), 73% of whom died during
hospitalisation, yielding a borderline significant positive association
between antimalarial administration and fatal outcome (OR 5.93,
95%CI: 0.93–50.5, Fisher’s exact p-value=0.05). However, two of
these patients received quinine, indicating more severe infection.
When these two were removed from analysis, and analysis was
restricted to patients receiving presumptive artemether/lumefan-
trine, the difference in clinical outcome was no longer significant
(p=0.23). Oral rehydration solution (ORS) was administered to
16 patients (84%), while four patients (21%) received IV-fluids.
Vitamin supplementation was not recorded. With the exception of
antimalarial treatment, there was no significant difference in
clinical outcome for any treatment component (Fisher’s exact p-
value range 0.33–1.00).
Of the ten patients whose axillary body temperature was
recorded at least once during hospitalisation, five (50%) had their
temperature recorded at least once daily for 80% of their stay,
while seven (70%) had their temperature recorded at least once
daily for 50% of their stay (data not shown). Heart rate, respiratory
rate, and blood pressure were not recorded for any patients.
Discussion
This study documents clinical manifestations of human BEBOV
infection among hospitalised patients and describes case manage-
ment strategy. Documenting clinical manifestations from a
putatively novel EBOV species furthers knowledge of human
filovirus infection, while describing case management identifies
areas for improvement and accentuates the need to assess
effectiveness of supportive treatment in future outbreaks.
Case fatality ratio
To date, the 25% crude CFR of the 2007–2008 Bundibugyo
outbreak is the lowest of recorded major human EHF outbreaks
[8]. However, among hospitalised laboratory-confirmed patients
the CFR increases to 42%, similar to that found by MacNeil and
colleagues for laboratory-confirmed acute-phase samples [69] and
observed consistently in SEBOV [53–55,72] and occasionally in
ZEBOV [41,73] outbreaks. The low crude CFR could be biased
by false positives among putative cases [8] or more accurate due to
inclusion of less severe cases who did not attend hospital.
Attributing differences in CFRs to specific filovirus species merits
caution, as disease recognition often requires a functioning
surveillance system and case-fatality is influenced by numerous
factors beyond viral species, including route and dose of infection,
genetic susceptibility, and underlying prevalence of immunodefi-
ciency and co-morbid conditions [16,49,54].
Figure 3. Median duration in days of symptoms from self-reported onset until clinical outcome among 26 symptomatic laboratory-
confirmed Ebola haemorrhagic fever patients, Bundibugyo District, Uganda (November 2007–February 2008). Blue and red bars
indicate general and haemorrhagic symptoms, respectively. *Day 0=presentation to the Ebola ward.
{Whiskers indicate maximum duration of the
self-reported symptoms prior to presentation to the Ebola ward for patient observations .1.
{Whiskers indicate maximum duration of the clinician-
assessed symptoms at presentation to and during hospitalisation on the Ebola ward for patient observations .1.
#Denominator contains female
patients only (n=9).
doi:10.1371/journal.pone.0052986.g003
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Similar to some previous filovirus outbreaks, this study
population only comprised adults (20–66 years) [49,74,75]. All
study patients reporting contact reported direct contact (11/14) or
direct contact with a potentially infected corpse during funeral
practices (3/14). Direct and funeral contacts were frequent
opportunities for disease transmission in previous filovirus
outbreaks [33,49,75–78]. However, 46% (12/26) of our study
population reported no known contact history. This may be due to
non-rigorous patient interviews during high-workload periods on
the Ebola ward. Considerable amounts of routine data were
missing (e.g. 54%, or 14/26 of study subjects did not have their
occupation recorded), indicating shortcomings in data collection.
Alternatively, primary or unnoticed secondary transmission could
have occurred. Available data preclude decisive conclusions.
Regrettably, incubation periods were not measured for this
study population. Albeit challenging to establish as an individual
may have had prolonged contact with a source case, it is possible
to obtain quality contact history and incubation-period data
[9,28,40,41,46–49,53,55,67,69,79]. Contact history data facilitate
outbreak control efforts and further understanding of transmission
patterns [33], while incubation time-period contributes to the
understanding of disease course in humans [35,80]. Without
complete and accurate data, interpretation of demographic
distribution and contact history is difficult. Authors are, for
example, precluded from explaining why 73% of the study
population were male.
Clinical manifestations
Ebola-ward clinicians working on the fully functional ward
employed a standardised prospective case reporting form for the
Bundibugyo outbreak and prioritised data transfer outside the
ward [19,81,82]. Subsequent analyses (Tables 2, 3; Figures 2 and
3) document the first recognized observation of human disease
caused by this putatively novel EBOV species and further
knowledge of FHF clinical manifestations and disease course.
Symptoms previously observed and reported from human
ZEBOV [28,40–52], SEBOV [53–55], CIEBOV [9], and MARV
[19,33,57–67] infections are congruous with these clinical data. A
more detailed comparison is not feasible due to substantial
variations in FHF reporting methodology.
As filovirus ward clinicians often use personal discretion to
decide whether an individual should proceed to a diagnostic test
and hospitalisation or return to the community [33], these
documented BEBOV clinical manifestations could potentially
assist future FHF clinical case identification efforts. For example,
the supposed filovirus disease hallmarks (fever plus haemorrhage)
were observed relatively infrequently (3/26; 12%) in this study
population. Three individuals prior to hospitalization reported
fever plus haemorrhage, no individual whose axillary temperature
was recorded at presentation to the Ebola ward had fever, and one
Figure 4. Frequency of haemorrhagic symptoms from self-reported day of symptom onset to clinical outcome, as absolute
numbers and percentages, among symptomatic (9 deceased and 12 surviving) laboratory-confirmed Ebola haemorrhagic fever
patients, Bundibugyo District, Uganda, November 2007–February 2008. Note changes in denominator between self-reported and clinically
observed sections.
doi:10.1371/journal.pone.0052986.g004
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hospitalised patients. The most frequent clinically observed
symptoms in this study population (i.e. severe headache, asthenia,
myalgia) are subjective and could equally indicate typhoid,
shigellosis, or other endemic diseases. In outbreak settings, authors
recommend continued rigorous study of human FHF clinical
manifestations to increase the accuracy of clinical detection of
filovirus infection, a crucial aspect of outbreak control [28–33].
Further improvements to diagnostic accuracy beyond that
achievable through clinical and epidemiological data will require
the consistent and timely dispatch of field laboratories to filovirus
outbreak settings and an eventual development of a bedside
diagnostic (e.g. dipstick test).
Comprehensive documentation and understanding of FHF
clinical manifestations is needed, as the administration of
treatment regimens should be based on presentation, anticipated
symptomatology, and disease severity. Authors recommend that
future clinical reporting employ an improved version of the report
form, further justification of which is delineated below [19].
Case management
Data indicate that components of standard treatment were not
comprehensively administered and monitoring was infrequent or
non-existent. All patients should have received antibiotics and
antimalarials, but these were recorded for only 27% and 42% of
patients respectively. Data preclude determining whether this was
warranted or rather demonstrate sub-standard treatment, incom-
plete data recording, or both. Lack of recorded data on symptoms
was associated with 74% increased odds of death, suggesting a
possible relationship between data recording and outcome, though
statistical significance was not reached. (OR 1.74; 95%CI: 0.23–
15.06).
Measurement of axillary body temperature, a basic non-invasive
procedure, was recorded sporadically, if at all. Only 19% (5/26) of
patients had axillary body temperature recorded at least once per
day for 80% of their hospital stay. This indication of sub-standard
patient monitoring affects interpretation of the finding that only
one patient developed fever for one day during hospitalisation. It is
questionable whether this accurately reflects fever frequency for
BEBOV infection, which seems likely to have been more frequent
than data indicate. Sub-standard patient monitoring is also
discernable from the lack of heart rate, respiratory rate, blood
pressure and laboratory-based biochemical patient monitoring
data. Since the use of stethoscopes and sphygmomanometers was
prevented by safety concerns, it is important to develop a protocol
for safe usage of such basic monitoring tools on a filovirus ward.
Authors advocate for a high-biosafety field laboratory to be located
near-by future outbreak epicentres so that diagnostic results are
available within hours. It would also be highly desirable if
laboratory testing additionally included the monitoring of patient’s
biochemical parameters. Patient monitoring must improve sub-
stantially if treatment regimens are to incorporate additional
elements of intensive care (e.g. correcting electrolyte and metabolic
imbalances, managing goal-directed haemodynamics, supplement-
ing oxygen, and mitigating strong inflammatory responses and
disseminated intravascular coagulation) or be subjected to rigorous
evaluation.
While antibiotics and antimalarial administration and standard
patient monitoring are deliverables for all patients, other treatment
components are administered as indicated by symptomatology or
disease severity. However, as in other data collection initiatives
[19], we lack disease severity data. For example, did only 69% of
patients experience mild pain and appropriately receive paracet-
amol for its alleviation, or did other patients also experience pain
and not receive pain relief? This difficulty in interpretation also
applies to administration of cimetidine, IV-fluids, and ORS
Table 3. Treatment recorded for 19 hospitalised laboratory-confirmed Ebola haemorrhagic fever patients, by clinical outcome.
Treatment Survived (%)
1 Died (%)
1 OR (95%CI)
2
Any recorded treatment 8 (47) 9 (53) 5.04 (0.54-inf)
Pain relief
Paracetamol 3 grams/day 9 (50) 9 (50) 1.48 (0.25–9.82)
Fluids 9 (56) 7 (44) 0.78 (0.14–4.46)
ORS alone 9 (56) 7 (44) ..
ORS and Ringers lactate+GL 5% 3l 2 (100) 0 (0) ..
ORS and Ringers lactate+dextrose 5%2l 0 (0) 2 (100) ..
Antimalarials 3 (27) 8 (73) 5.93 (0.93–50.5)
Artemether/lumefantrine 3 (33) 6 (67) ..
Quinine 0 (0) 2 (100) ..
Antibiotics 3 (43) 4 (57) 1.74 (0.23–15.1)
Amoxicillin 1 (25) 3 (75) ..
Ciprofloxacin 2 (100) 0 (0) ..
Ceftriaxone 0 (0) 1 (100) ..
Dyspepsia relief
Cimetidine 0 (0) 1 (100) –
Bundibugyo District, Uganda, November 2007–February 2008.
NB:
1Row percentages.
2OR calculates the odds ratio for fatal outcome and 95% confidence intervals, comparing patients who received treatment to those who did not, using exact methods
and Fisher’s exact p-values for small sample sizes (confounders have not been adjusted for due to small cell sizes).
doi:10.1371/journal.pone.0052986.t003
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Organizations responsible for filovirus patient management
should, prior to the next outbreak, consider these shortcomings
and improve standardised data collection accordingly.
Study limitations
Data were collected from laboratory-confirmed EBOV hospi-
talised patients on the two Ebola wards and not from the
additional 30 laboratory-confirmed cases identified in the com-
munity [69]. Individuals receiving hospital care may differ from
those not seeking and receiving such care. For example, the latter
may have less severe disease and survive more frequently, thus
explaining the overall lower CFR compared to the one observed in
hospitalised laboratory-confirmed patients (25% versus 42%).
Moreover, limited data were collected from patients hospitalised
early in the outbreak, as clinical data collection was not a priority.
Authors were limited to describing administered treatment
rather than assessing its impact on clinical outcome. The small
sample size and incomplete monitoring data precluded adjusting
for potential confounding (e.g. by disease severity) of any
association between treatment and clinical outcome. For instance,
the borderline association of antimalarial treatment with fatal
outcome could be explained by patients receiving this treatment
being more severely ill with malaria or Ebola than those who did
not.
Recommendations for improving data collection in
filovirus outbreaks
Likely reasons for incomplete patient monitoring and possible
sub-standard treatment delivery include: (i) non-prioritization of
systematic clinical data collection due to heavy workloads,
particularly during the height of the outbreak, (ii) recording of
patient data on multiple forms or blank paper, increasing
likelihood of data mismanagement or loss, and (iii) lack of staff
awareness of the importance and reasons for clinical data
recording and supportive case management during filovirus
outbreaks. Organizations responsible for filovirus patient manage-
ment thus need clear and concise guidelines, training, and supplies
to improve data collection and case management components,
similar to those used for intensive care patients in industrialized
countries.
Those responsible for filovirus case management must ensure
that sufficient supplies and equipment (e.g. thermometer, time-
piece measuring seconds, stethoscope, and sphygmomanometer, as
used for previous filovirus patients [9,19,43,47,55,67]) and
standardised data collection forms are available at outbreak
response initiation. Together with appropriate training and
comprehensive supportive treatment, appropriate supplies would
facilitate clinicians’ efforts to deliver optimal care to future patients
and enhance analyses of accurate epidemiological and clinical
data, both crucial for advancing outbreak control and treatment
efforts for poorly understood filovirus diseases.
Finally, laboratory tests (e.g. haemoglobin, complete and white
blood cell counts) performed in past outbreaks [9,19,43,47,55,67],
should be included in routine filovirus patient monitoring. On-site
laboratory capacity would greatly facilitate case management
efforts through the provision of timely diagnostic and patient status
results. The authors recommend on-site diagnostic and biochem-
ical laboratory capacity where possible in subsequent outbreaks
[29,33,34].
Conclusions
Authors did not find important differences between the
symptomatology of BEBOV and other FHF strains. Results did
not confirm the remarkably low case fatality reported initially [8],
but are similar to MacNeil and colleague’s findings among
confirmed BEBOV cases [69]. Experiencing any haemorrhagic
symptom significantly increased the probability of patient death.
Each additional symptom increased the odds of death, suggesting
that total symptom load is a risk factor.
Recordkeeping and data collection were poor in both makeshift
and fully functional Ebola wards. Standardising and strengthening
data collection and recordkeeping on Ebola wards will help
address the uncertainties discussed in this paper. Improved
documentation and monitoring is a prerequisite for intensifying
supportive care in future outbreaks. Safety protocols should be
reviewed where they appear to compromise patient monitoring
and care without significantly improving safety.
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